<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190593</url>
  </required_header>
  <id_info>
    <org_study_id>1865</org_study_id>
    <secondary_id>H3S-MC-GGIO</secondary_id>
    <nct_id>NCT00190593</nct_id>
  </id_info>
  <brief_title>Raloxifene Use for The Heart</brief_title>
  <official_title>Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether raloxifene compared with placebo lowers the
      risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal
      women at risk for major coronary events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first occurrence of invasive breast cancer after an expected 5 to 7.5 years of follow-up.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>After an expected 5 to 7.5 years of follow-up:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death, non-fatal MI, hospitalized acute coronary syndrome other than MI, myocardial revascularization, and stroke (individually and combined)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalization and mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-coronary artery revascularization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-traumatic lower extremity amputation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism.</measure>
  </secondary_outcome>
  <enrollment>10000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raloxifene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with established coronary heart disease or at risk for a major
             coronary event.

        Exclusion Criteria:

          -  Postmenopausal symptoms that required estrogen replacement therapy.

          -  Suspected or known history of breast or endometrial carcinoma.

          -  Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal
             vein thrombosis.

          -  New York Heart Association classes III or IV heart failure.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A, Baygani SK, Anderson PW, Moscarelli E. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol. 2002 Dec 1;90(11):1204-10.</citation>
    <PMID>12450599</PMID>
  </reference>
  <reference>
    <citation>Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol. 2001 Aug 15;88(4):392-5.</citation>
    <PMID>11545760</PMID>
  </reference>
  <results_reference>
    <citation>Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006 Jul 13;355(2):125-37.</citation>
    <PMID>16837676</PMID>
  </results_reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 24, 2007</last_update_submitted>
  <last_update_submitted_qc>January 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

